Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis

J. C. Nichols, Gregory James Gores, Nicholas F La Russo, R. H. Wiesner, D. M. Nagorney, R. E. Ritts

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) predisposes to the development of cholangiocarcinoma, a usually fatal complication that is difficult to diagnose. Serum concentrations of CA 19-9, a tumor-associated antigen, are frequently increased in patients with only cholangiocarcinoma. The aim of this study was to assess the value of an increased serum CA 19-9 level for the diagnosis of cholangiocarcinoma in patients with preexisting PSC. We analyzed serum samples from 9 patients with PSC and superimposed cholangiocarcinoma and from 28 patients with only PSC. Serum concentrations of CA 19-9 were measured in a blinded manner with use of an immunoradiometric assay. The serum CA 19-9 concentrations were increased in 8 of 9 patients (89%) with PSC and cholangiocarcinoma (mean ± SE, 391 ± 86 U/ml; range, 4 to 677), whereas they were increased in only 4 of 28 patients (14%) with only PSC (mean ± SE, 61 ± 16 U/ml; range, 2 to 370). The sensitivity of a CA 19- 9 value greater than 100 U/ml for cholangiocarcinoma in PSC was 89%, and the specificity was 86%. The measurement of serum concentrations of CA 19-9 is a promising test for detecting cholangiocarcinoma in patients with PSC.

Original languageEnglish (US)
Pages (from-to)874-879
Number of pages6
JournalMayo Clinic Proceedings
Volume68
Issue number9
StatePublished - 1993

Fingerprint

Sclerosing Cholangitis
Cholangiocarcinoma
Serum
Immunoradiometric Assay
Neoplasm Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. / Nichols, J. C.; Gores, Gregory James; La Russo, Nicholas F; Wiesner, R. H.; Nagorney, D. M.; Ritts, R. E.

In: Mayo Clinic Proceedings, Vol. 68, No. 9, 1993, p. 874-879.

Research output: Contribution to journalArticle

@article{a85822fc26084ef69bdbd850fe28fc9b,
title = "Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis",
abstract = "Primary sclerosing cholangitis (PSC) predisposes to the development of cholangiocarcinoma, a usually fatal complication that is difficult to diagnose. Serum concentrations of CA 19-9, a tumor-associated antigen, are frequently increased in patients with only cholangiocarcinoma. The aim of this study was to assess the value of an increased serum CA 19-9 level for the diagnosis of cholangiocarcinoma in patients with preexisting PSC. We analyzed serum samples from 9 patients with PSC and superimposed cholangiocarcinoma and from 28 patients with only PSC. Serum concentrations of CA 19-9 were measured in a blinded manner with use of an immunoradiometric assay. The serum CA 19-9 concentrations were increased in 8 of 9 patients (89{\%}) with PSC and cholangiocarcinoma (mean ± SE, 391 ± 86 U/ml; range, 4 to 677), whereas they were increased in only 4 of 28 patients (14{\%}) with only PSC (mean ± SE, 61 ± 16 U/ml; range, 2 to 370). The sensitivity of a CA 19- 9 value greater than 100 U/ml for cholangiocarcinoma in PSC was 89{\%}, and the specificity was 86{\%}. The measurement of serum concentrations of CA 19-9 is a promising test for detecting cholangiocarcinoma in patients with PSC.",
author = "Nichols, {J. C.} and Gores, {Gregory James} and {La Russo}, {Nicholas F} and Wiesner, {R. H.} and Nagorney, {D. M.} and Ritts, {R. E.}",
year = "1993",
language = "English (US)",
volume = "68",
pages = "874--879",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis

AU - Nichols, J. C.

AU - Gores, Gregory James

AU - La Russo, Nicholas F

AU - Wiesner, R. H.

AU - Nagorney, D. M.

AU - Ritts, R. E.

PY - 1993

Y1 - 1993

N2 - Primary sclerosing cholangitis (PSC) predisposes to the development of cholangiocarcinoma, a usually fatal complication that is difficult to diagnose. Serum concentrations of CA 19-9, a tumor-associated antigen, are frequently increased in patients with only cholangiocarcinoma. The aim of this study was to assess the value of an increased serum CA 19-9 level for the diagnosis of cholangiocarcinoma in patients with preexisting PSC. We analyzed serum samples from 9 patients with PSC and superimposed cholangiocarcinoma and from 28 patients with only PSC. Serum concentrations of CA 19-9 were measured in a blinded manner with use of an immunoradiometric assay. The serum CA 19-9 concentrations were increased in 8 of 9 patients (89%) with PSC and cholangiocarcinoma (mean ± SE, 391 ± 86 U/ml; range, 4 to 677), whereas they were increased in only 4 of 28 patients (14%) with only PSC (mean ± SE, 61 ± 16 U/ml; range, 2 to 370). The sensitivity of a CA 19- 9 value greater than 100 U/ml for cholangiocarcinoma in PSC was 89%, and the specificity was 86%. The measurement of serum concentrations of CA 19-9 is a promising test for detecting cholangiocarcinoma in patients with PSC.

AB - Primary sclerosing cholangitis (PSC) predisposes to the development of cholangiocarcinoma, a usually fatal complication that is difficult to diagnose. Serum concentrations of CA 19-9, a tumor-associated antigen, are frequently increased in patients with only cholangiocarcinoma. The aim of this study was to assess the value of an increased serum CA 19-9 level for the diagnosis of cholangiocarcinoma in patients with preexisting PSC. We analyzed serum samples from 9 patients with PSC and superimposed cholangiocarcinoma and from 28 patients with only PSC. Serum concentrations of CA 19-9 were measured in a blinded manner with use of an immunoradiometric assay. The serum CA 19-9 concentrations were increased in 8 of 9 patients (89%) with PSC and cholangiocarcinoma (mean ± SE, 391 ± 86 U/ml; range, 4 to 677), whereas they were increased in only 4 of 28 patients (14%) with only PSC (mean ± SE, 61 ± 16 U/ml; range, 2 to 370). The sensitivity of a CA 19- 9 value greater than 100 U/ml for cholangiocarcinoma in PSC was 89%, and the specificity was 86%. The measurement of serum concentrations of CA 19-9 is a promising test for detecting cholangiocarcinoma in patients with PSC.

UR - http://www.scopus.com/inward/record.url?scp=0027236324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027236324&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 874

EP - 879

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -